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Abstract
Background—Adverse drug events (ADEs) associated with over-the-counter (OTC) medications 
cause 178,000 hospitalizations each year. Older adults, aged 65 and older, are particularly 
vulnerable to ADEs. Of the 2.2 million older adults considered at risk for a major ADE, more than 
50% are at risk due to concurrent use of an OTC and prescription medication.
Objectives—To refine the intervention and implementation strategy through diagnostic and 
formative evaluation; to evaluate the effectiveness of the intervention for preventing misuse of 
high-risk OTC medications by older adults; and to evaluate the implementation of the intervention 
in community pharmacies.
Methods—A system redesign intervention to decrease high-risk OTC medication misuse will be 
tested to reduce misuse by improving communication between older adults and community 
pharmacists via the following features: a redesign of the physical environment to sensitize older 
adults to high-risk OTC medications, and the implementation of a clinical decision tool to support 
the pharmacist when critically evaluating the older adult’s health status. The study will be 
conducted in three phases: a participatory design phase, a beta phase, and a test phase. The test 
phase will be conducted in three mass-merchandise stores. A total of 144 older adults will be 
recruited. A pre (control)/post (intervention) test will determine the effectiveness of the 
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intervention. The primary outcome will be a comparison of proportion of older adults who misuse 
OTC medication from baseline to post-intervention. The process of implementation in the 
community pharmacy setting will be evaluated using the taxonomy proposed Proctor et al. The 
participatory design phase has been approved by the institution’s IRB (2016-0743).
Projected Impact—We anticipate that this project, which focuses on achieving systems-based 
improvement in an underemphasized area of the medication use process, will reduce ADEs 
associated with inappropriate OTC medication use in older adults.
Keywords
Medication safety; Community pharmacy; Dissemination and implementation; Older Adults; 
Hybrid design
Background
Older adults are at high risk of significant harm associated with over the counter (OTC) 
medication use. Of the estimated 2.2 million older adults who are at risk of a major adverse 
drug event (ADE), more than 50% of these interactions involve an OTC medication.1 Four 
of the 10 most frequently used drugs are available OTC. They are: ibuprofen, aspirin, 
acetaminophen, and diphenhydramine. These four drugs also are available in multiple-
ingredient preparations, accounting for 45% of acetaminophen and 26% of aspirin use, thus 
increasing the potential for dangerous overdosing.2 Older adult use of non-steroidal anti-
inflammatory drugs (NSAIDs), such as ibuprofen and aspirin, results in 80,000 preventable 
ADEs each year. NSAID use accounts for a larger burden of ADEs (15.4%) than 
anticoagulants (10.2%), one of the Department of Health and Human Services’ top priority 
drugs in its National Action Plan for ADE prevention.3,4 Unintentional overdoses of 
acetaminophen result in 14,000 emergency department visits, and up to 50% of all acute 
liver failures per year.5,6 Diphenhydramine has anticholinergic properties which causes 
dizziness and loss of balance in 25% of older adults, which increases their risk of falling.7 
Of older adults taking diphenhydramine for sleep, 40% were also taking one or more 
anticholinergic medications concurrently, compounding the risk of ADEs.8 These four drugs 
represent a significant ADE burden, and are the focus of this study.
Most older adults are not familiar with the appropriate dosing of OTC medications or how 
OTC medications interact with their other medications. Compounding the lack of patient 
knowledge about OTC medications, providers do not know which OTC medications their 
patients are consuming.9 Such lack of awareness and documentation about OTC medication 
use may lead to duplication of therapies and dangerous overdosing. In fact, the Centers for 
Medicare and Medicaid Services single out diphenhydramine and NSAIDs for review 
specifically because of their OTC availability and potential for therapeutic duplication.10,11 
Despite the fact that OTC medication misuse is prevalent and costly, this potentially 
enormous patient safety gap remains relatively invisible. No effective interventions exist to 
help older adults prevent OTC medication misuse.
The availability of pharmacists at the point of sale of OTC medication has great potential for 
decreasing OTC medication misuse by older adults. A study found that 57% of elderly 
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patients taking chronic prescription and OTC medications were not taking their OTC safely 
and required a pharmacist intervention with their OTC medication.12 Moveover, 80% of 
Americans report they would purchase (or avoid) a particular OTC medicine based on their 
pharmacist’s recommendation.13 Unfortunately, the current suboptimal design of community 
pharmacies and lack of standardized processes contribute to misuse of high-risk OTC 
medications. OTC medications are displayed to improve profitability,14 not prevent 
medication misuse. Older adults, who tend to have more visual and cognitive impairment, 
can become overwhelmed when faced with poorly designed aisles of confusing OTC 
choices.15
In response to The Affordable Care Act legislation that expands health care coverage, many 
chain community pharmacy organizations are retooling themselves as a vital part of the 
health care system, by discontinuing the sale of tobacco, adding primary care health clinics, 
and redesigning the pharmacy to allow pharmacists to more easily interact with patients.16,17 
Although “health and wellness” is a focus of this nationwide movement, there is no specific 
emphasis on OTC medication safety. The present study provides a timely opportunity to 
expand the industry’s new initiatives to include system redesign to improve OTC medication 
use by older adults.
Few interventions have attempted to decrease misuse of high-risk OTC medications in older 
adults, and none have addressed system barriers.18 Compared to efforts to improve 
prescription medication safety,19,20 efforts to decrease OTC medication misuse in 
community-dwelling older adults have been practically ignored. To address this alarming 
and critical gap in medication safety, a system redesign intervention has been developed to 
mitigate system barriers. This intervention, which is grounded in human factors engineering 
principles and methods, includes a redesign of the community pharmacy’s OTC aisles, and 
the implementation of a pharmacist clinical decision tool. The intervention will decrease 
misuse by heightening older adults’ awareness of OTC risk, allowing pharmacy staff to see 
and initiate conversations with older adults in the aisles, and incorporating an efficient 
standardized process for pharmacists to gather necessary information to make 
recommendations.
The long term goal is to prevent OTC medication misuse and subsequent harm by targeting 
system barriers. A three-phase, pre (control)/post (intervention) study design to determine 
the intervention’s effectiveness in decreasing high-risk OTC medication misuse by older 
adults will be conducted. The hypothesis is that older adults who are more aware of risks 
and can more easily determine if those risks pertain to their own health situation by speaking 
with a pharmacist will safely select and not misuse high-risk OTC medications. Specifically, 
the aims are:
Aim 1. To refine the system redesign intervention and implementation strategy 
through diagnostic and formative evaluation. The two phase approach will comprise 
of a participatory design phase, and a beta test and refinement phase to produce a 
refined intervention and feasible implementation strategy.
Aim 2. To evaluate the effectiveness of a refined system redesign intervention for 
preventing misuse of high risk OTC medications by older adults. The hypothesis is 
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that communication with a pharmacist, facilitated by the pharmacy redesign and 
clinical decision tool, will prevent older adult misuse of OTC medications. This 
hypothesis will be tested by evaluating the potential misuse of OTC medications 
selected by older adults and comparing results prior to and after the implementation 
of the intervention.
Aim 3. To evaluate the implementation of a refined system redesign intervention in 
community pharmacies. By employing summative evaluation and assessing evidence-
based implementation outcomes, key intermediate outcomes will be identified and 
measured,21 including the intervention’s impact on pharmacists’ work and older 
adults’ decision making processes. These measures will inform the understanding of 
the potential feasibility and sustainability of widespread dissemination and 
implementation of the system intervention.
Conceptual Model
The conceptual framework for this intervention is adapted from the Systems Engineering 
Initiative for Patient Safety (SEIPS) 2.0 work system model to improve patient outcomes, a 
human factors engineering model developed by Holden et al.22 The SEIPS Model has been 
applied to frame the design and analysis of many patient safety studies, including research 
conducted in community pharmacies.23,24 The SEIPS 2.0 model is appropriate for this study 
because it emphasizes how work system barriers can impact the “work” conducted by 
pharmacists and older adults. Work is defined as goal-oriented, effortful activities.25 For 
pharmacists, work would include clarifying an older adult’s medication list or determining if 
the older adult should self-treat their stated problem. Older adult work would include 
determining how often to take an OTC medication or if an OTC medication interacted with 
prescription medication. This model is also appropriate because it highlights the importance 
of collaborative work, in which pharmacists and older adults are actively engaged agents, 
working together to achieve their goals. These work processes in turn affect older adult, 
pharmacist, and organizational outcomes.
Study Design Overview
In order to assess the effectiveness of the intervention while also understanding the context 
for implementation, an effectiveness-implementation hybrid design proposed by Curran et al 
will be utilized.26 A hybrid design, which blends design components of effectiveness and 
implementation research, improves the speed of knowledge creation and increases the 
usefulness and policy relevance of the research being conducted.27 In addition to a 
diagnostic and formative evaluation to refine the intervention (Aim 1), Curran’s hybrid Type 
2 design will be used in which Aim 2 is to determine the effectiveness of the intervention. 
An independent aim (Aim 3) is to pilot test an implementation strategy and to understand the 
context for widespread implementation through an examination of barriers and facilitators.
The study design includes three phases (Figure 1). Aim 1 (To refine the intervention and 
implementation strategy through diagnostic and formative evaluation) will comprise the first 
two phases. The two phases are a participatory design phase and a beta test and refinement 
phase. In the first phase, a participatory design approach will be used to fine-tune the 
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intervention. This phase will utilize a stakeholder group comprised of pharmacists, 
technicians, and older adults. The second phase will be a beta test of the intervention in one 
pilot store. During the beta phase, the intervention will be pilot tested with a total of 24 older 
adult participants. OTC medication selection and reported use information will be collected 
at baseline and post-intervention. Members of the participatory design group will convene to 
discuss results from the beta test. Actionable barriers identified during the beta test will be 
discussed and formative evaluation will be used to refine and improve the implementation 
process and optimize the intervention.28
In the third phase, a pre (control)/post (intervention) test will be conducted to determine the 
effectiveness of a refined system redesign intervention to decrease OTC medication misuse 
in older adults (Aim 2) and understand the process of implementation in the community 
pharmacy setting (Aim 3). The third phase will include the collection of baseline data 
followed by the implementation of the refined intervention and collection of post-
intervention data in three different stores. A total of 144 older adult participants will be 
recruited.
The System Redesign Intervention
A system redesign intervention, grounded in the SEIPS 2.0 model that addresses both 
pharmacist and older adult barriers to decreasing OTC medication misuse has been 
conceptualized. The intervention will maintain the autonomy and self-care engagement, 
while improving the selection behaviors of older adults. The intervention will improve 
communication by facilitating a collaborative process and will include two components:
1. Physical layout redesign: The physical layout of the OTC aisles will be 
redesigned to facilitate pharmacist-older adult communication. The redesign will 
have two parts:
a. The high-risk OTC medications (e.g., pain, sleep, cough/cold) currently 
displayed in one aisle that is not within the line of sight of and 
relatively far away from the prescription department, will be moved to 
the aisle closest to the prescription department and within line of sight 
of the pharmacists and technicians.
b. Signage will be installed and aisle redesign will take place to denote the 
OTC medications that are typically not safe for older adults. Human 
factors principles associated with vision, contrast, symbols, and color to 
denote warning will be incorporated to architect safe decision 
making.29 Given that much of OTC medication selection occurs based 
on prior experiences, the content of the signs will trigger older adults to 
question their selection of an OTC with regards to a safe and effective 
choice. This content helps older adults recognize they may lack the 
knowledge necessary to make an appropriate decision.
2. Clinical Decision Tool: Because pharmacists have almost no information when 
making OTC recommendations, they must ask a number of time-consuming 
questions to the older adult to determine what might be appropriate. The OTC 
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clinical decision tool was developed from pharmacist focus groups.30 The 
purpose for the clinical decision tool is to help the pharmacist efficiently gather 
relevant information by using an algorithm for the information that the 
pharmacist seeks to establish about an older adult, and the sequence for gathering 
specific information. Consistent with previously reported successful 
interventions,31 the tool provides a list of criteria arranged in a systematic 
manner, allowing the pharmacist to ensure that all criteria are considered. The 
tool serves as a cognitive aid which provides a framework for grouping specific 
information. This can help improve memory recall and provide a standardized 
framework for evaluation.
Study Sites
This study will take place in four mass merchandise stores in Wisconsin that are part of the 
same pharmacy organization (one store in the beta phase, and three stores in the test phase). 
These stores were selected because they represent a variety of communities that vary by the 
size of the population, proportion of older adults, and socioeconomic status. Pharmacists 
working at these stores have been identified as potential champions of this intervention, and 
could serve as mentor coaches when the project is scaled up to more stores.
Phase 1: Participatory Design Approach to Fine-tune Intervention and Implementation 
Strategy
Participatory design is an approach to design that actively involves all stakeholders at several 
stages of the innovation process to help ensure the result meets their needs and is usable.32 
The participatory design approach will be taken using a stakeholder group consisting of up 
to five older adults, four pharmacists, and one technician. Pharmacy staff and older adults 
will be recruited from stores in the same pharmacy organization.
Six meetings with all stakeholders will be scheduled to fine-tune the intervention 
components and implementation strategy. Initially, the meetings with pharmacy stakeholders 
and older adults will be separate, as their concerns may be different. The focus will be on 
articulating and verifying the needs of older adults. The initial meetings will be used to build 
trust and buy-in, and to discuss their ideas about how data collection and the intervention 
can be incorporated into their current work processes. At least one of the later meetings will 
take place at the store that will serve as the beta site. This will allow pharmacy stakeholders 
and older adults to visualize how the OTC aisle will be moved and redesigned, and how the 
pharmacist and/or technician may easily and efficiently approach and interact with older 
adults when selecting and recommending OTC medications. Stakeholders will help inform 
the signage that will be used to denote potentially unsafe OTC medications.
It is anticipated that the majority of older adult stakeholders will be white. In order to 
capture the perspectives of a more diverse group, the Community Advisors on Research 
Design and Strategy (CARDS)33, a core service of the Wisconsin Network for Research 
Support in the UW School of Nursing will be consulted. CARDS are focus groups of 
community members from diverse racial, ethnic, socioeconomic, and educational 
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backgrounds. They are trained to give constructive feedback to researchers on how to make 
materials accessible for diverse groups of people.
Phase 2: The Beta and Refinement Phase
In order to optimize the intervention and the likelihood of affecting change, a beta test of the 
intervention will be conducted. The results of the beta test will inform the development of a 
refined intervention. Before, during, and after the beta test implementation, effectiveness and 
implementation outcomes will be analyzed to resolve actionable barriers, enhance identified 
levers of change, and refine components of the intervention.
The research team will use an iterative approach to discuss the results and to assess the data 
gathered during the beta test. Stakeholders from the participatory design group and CARDS 
will be consulted to address unanticipated barriers. Actionable barriers identified in the beta 
test will be discussed and formative evaluation data will be used to refine and improve the 
implementation process and optimize the intervention.28 Insights gained in the recruitment 
strategy, data collection tools, how the clinical decision tool is used, pharmacist training, and 
signage and aisle redesign will be incorporated into the refined intervention and 
implementation strategy that will be used in the test phase.
Pharmacist, Technician, Store Manager Recruitment—Two pharmacists, two 
technicians, and one store manager will be recruited. The two pharmacists and one 
technician will fulfill two roles in the study: research personnel and study participants. 
Research personnel will participate in eight hours of human subjects and clinical decision 
tool training.
Older Adult Participant Recruitment—The study population will be older adults aged 
65+ who have received at least one prescription at one of the study stores in the last 12 
months, and indicate that they intend to purchase an OTC medication from one of the 
following categories: pain, sleep, cough/cold. The participants must be able to provide 
written informed consent and speak English. Prior to baseline and post-intervention, up to 
two mailings of a random sample of 100 patients will be sent to patients aged 65+ who have 
received a prescription at the beta site store in the last 12 months. The mailing will invite 
them to participate, and will include an information sheet and study flier. The random 
sample invited to participate in the baseline data collection at each store will be a different 
sampling frame than the post-intervention sample.
The letter will direct older adults to call the research coordinator on the telephone if they are 
interested in participating. The letter will also identify a study liaison at the beta store. This 
individual will be one of the technicians who works at the beta store. This study liaison will 
answer questions, and assist the older adult in contacting the research coordinator if he/she 
chooses to participate. If the older adult agrees to participate, the research coordinator will 
set up an appointment to meet the participant at the store, and mail the informed consent 
form and medical/demographic form for the participant to complete prior to the 
appointment. Participants will receive $20 cash for participating.
Chui et al. Page 7
Res Social Adm Pharm. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
During the beta phase, a total of 24 participants from one store will be recruited: 12 
participants during baseline data collection and 12 participants during the post-intervention 
data collection.
Data Collection—During the beta phase, information that both sheds light on how to 
optimize the intervention (effectiveness outcomes), and information that will facilitate a 
smooth implementation (implementation outcomes) will be collected. The taxonomy of 
implementation outcomes proposed by Proctor et al will be applied.21 A summary of all 
outcome variables and data sources are provided in Table 1.
Older Adult Medical/Demographics form: The form will include the self-report of disease 
information using the OAR questionnaire,34 prescription and OTC medications, and 
demographic information.35 Participants recruited at both baseline and post-intervention will 
complete the form.
Older Adult Interviews: Each consented older adult will participate in a face to face 
“walking” interview in which a trained researcher will ask the older adult to articulate the 
medication they are searching for and the decisions involved in making the selection. These 
probes will help us understand the older adult’s so-called “work,” (goal-oriented effortful 
activities) as they select an OTC medication. Following the walking interview, a short semi-
structured interview will be conducted to gather information on how the older adult intends 
to use the medication (e.g. dosing and duration).35 Additionally, for those older adults 
participating in the study post-intervention, questions will be posed specifically related to 
the feasibility, usefulness, and acceptance of the intervention.
Older Adult Satisfaction Survey: A community pharmacy satisfaction scale developed by 
Kassam et al was adapted.36 This survey will be administered at both baseline and post-
intervention during the beta phase. The survey measures three important components that are 
hypothesized will show improvement post-intervention: care plan development, information 
and education, and collaborative care. This survey will be completed by older adults at the 
end of the interview.
Pharmacist/Technician Observations: The purpose of the observations is to gain insight 
on fit and compatibility of the intervention within the pharmacist’s and technician’s work 
system. A total of four 3-hour observations (two during baseline and post-intervention) will 
be conducted at the beta site. The focus of the observations will be how the intervention 
impacts pharmacists’ and technicians’ work with a focus on how they incorporate this added 
responsibility into their workflow. Observational data will be recorded by hand and then be 
transcribed into typed notes.23,37,38
Pharmacist/Technician Tool Acceptance Survey: A technology acceptance survey that has 
been previously used by Holden et al. was adapted to explore perceived ease of use, 
perceived usefulness to the pharmacist and older adult, behavioral intention to use, and 
satisfaction with the clinical decision tool.39 The two pharmacists and two technicians from 
the beta site store will be administered the survey four weeks after the intervention is 
implemented.
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Pharmacist/Technician/Store Manager/Administrator Interviews: Interviews will be 
conducted with two pharmacists, two technicians, one store manager, and one administrator 
to elicit descriptions of each respondent’s role and how the intervention was implemented in 
their store. Guided by the components of the SEIPS 2.0 model, facilitators and barriers 
related to each implementation outcome will be probed.23,37,40–42
Pharmacist OTC Encounter Form: The purpose of the Pharmacist OTC Encounter Form 
are: 1) to document the interactions that pharmacists have with consumers (study 
participants and non-participants) regarding OTC medications, 2) provide a reliability check 
for the data collected during the older adult participant interviews, and 3) pilot-test a quick 
and simple data collection tool that may be used during a future scaled up intervention.
The encounter form will be used to collect recommendation characteristic outcomes that are 
in addition to the primary outcome of OTC medication misuse (e.g., referral to a physician, 
behavioral or medication recommendations). Further, the encounter form will be used to 
quantify the time required to interact with consumers before and after the intervention is 
implemented.
Following each interaction, the pharmacist will document the interaction into a web-based 
application loaded on a tablet computer. The questions on the form include who initiated the 
conversation, whether the pharmacist left the prescription department to help the consumer, 
the problem or issue, recommendations that the pharmacist made, level of confidence in 
OTC guidance, and perceived time required to help the consumer. There will also be an 
optional open text box for pharmacists to type free text. In order to minimize the data 
collection burden, the beta phase pharmacists will collect encounter data for one week at 
three time points: 1) two weeks prior to intervention implementation, 2) two weeks after 
implementation, and 3) four weeks after implementation.
Data Analysis—The focus of the data analysis during the beta phase will be to learn how 
to improve the intervention and implementation strategy for the test phase.
Primary Outcome - OTC Medication Misuse: The OTC medication misuse outcome will 
be dichotomized into “safe use” or “misuse”. The same criteria used in a pilot study will be 
used to determine if an OTC medication that was selected is considered appropriate use or 
misuse. The four types of potential misuse include: 1) drug-drug interaction,43 2) drug-
disease interaction44 3) drug-age interaction44 and 4) reported usage that exceeded product 
labeling guidelines. A simple chi-square analysis will be done to conduct a univariate 
comparison of proportions of older adults who misuse OTC medications from baseline to 
post-intervention. The total and type of misuse will be quantified and compared to determine 
if the intervention reduces the frequency or instances of concurrent misuse.
OTC Decision Process Mapping: Using data from the older adult interviews, a cognitive 
task analysis45–47 will be conducted to compare the decision making processes of the older 
adults at baseline and post-intervention. The hypothesis is that the intervention will impact 
the decisions of older adult and will predict medication choice appropriateness. This method 
of analysis will serve as a mediator of the effect of the intervention and will allow the 
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research team to identify where the intervention improves decision making (e.g. reduces the 
number of choices) and where it does not (e.g. information is still hard to process).
Pharmacist OTC Encounter Form: At 2 and 4 weeks post-intervention, the number of 
pharmacist recommendations made, the types of recommendations, drug recommendations, 
non-drug recommendations including behavioral modifications or referral to physician, and 
confidence in making recommendation will be compared.
Quantitative Survey Data Analysis: For the pharmacist/technician tool acceptance survey, 
scores for each domain will be calculated by taking the mean of all item responses from that 
scale, and descriptive statistics will be calculated. For the older adult satisfaction survey, 
descriptive statistics and t-tests will be conducted to compare mean domain scores between 
the baseline and post-intervention time points.
Qualitative Data Analysis: Qualitative data from observations and interviews will be 
subjected to rigorous qualitative data analysis using techniques employed in previous 
pharmacy medication safety qualitative research.23,30,37,40–42,48,49 A deductive content 
analysis, discovering patterns, themes and categories in the data, will be used and guided by 
the theory-based approach.50 A conceptual coding structure will be created and as each 
interview or observation transcript is added to the analysis, passages will be classified 
according to existing codes, and codes will be added as needed.
Phase 3: The Test Phase
The test phase will be conducted to evaluate the effectiveness and implementation of the 
refined system redesign intervention in community pharmacies. A pre (control)/post 
(implementation) test will be conducted in three different stores.
Aim 2. Evaluate the effect of a system redesign intervention on preventing 
misuse of high-risk OTC medications by older adults—The primary study outcome 
of this study is the change in the proportion of older adults who misuse OTC medications. 
Secondary outcomes include an evaluation of older adult decision making processes and the 
pharmacist recommendation characteristics.
Sample Size Calculations—The sample size power calculation was focused on the 
primary outcome of Aim 2, to “evaluate the effect of a system redesign intervention on 
improved OTC medication selection by older adults,” collected during the test phase only. 
One small study found that 43% of older adults used an OTC medication safely. This is 
higher than the pilot work which found that only 5% of the study population took an OTC 
medication safely.35 Therefore, it is believed that older adult safe OTC medication use to be 
in the 5–43% range. In comparison, another study found that 82% of patients report that they 
would purchase (or avoid) a particular OTC medication based on their pharmacist’s 
recommendation.
The proportion of older adults who safely use OTC medications was conservatively 
estimated to increase from 40% to 65%. Based on a two-level (subjects level-1 nested under 
pharmacist level-2) logistic regression model with 80% power at a 0.05 significance level to 
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detect pre-post group differences, the study would meet power requirements (1−β =.80, 
α=0.05) with a sample size of 8 older adults (per pharmacist assessed twice, for nine 
pharmacists) for each baseline and post-intervention data collection period. The total number 
of older adults required for the test phase of study will be 144 (48 older adults recruited in 
each of three test site stores).
Pharmacist, Technician, and Older Adult Recruitment, and Data Collection—
The same recruitment strategy will be used as in the beta test. A total of three pharmacists, 
two technicians, and one store manager in each of the three test phase stores will be 
recruited. A total of 144 participants in the test phase will be recruited through up to three 
waves of mailings for the baseline and post-intervention data collection, at each store.
The same effectiveness outcomes of OTC medication misuse, older adult decision making 
processes, and recommendation characteristics will be collected, as in the beta phase. A total 
of nine pharmacists and six technicians will complete the interview and Tool Acceptance 
Survey.
Data Analysis
Primary Outcome - OTC Medication Misuse: The OTC medication misuse outcome will 
be dichotomized into “safe use” or “misuse”. The four types of potential misuse include: 1) 
drug-drug interaction,43 2) drug-disease interaction44 3) drug-age interaction44 and 4) 
reported usage that exceeded product labeling guidelines.
In order to assess if the OTC medication is considered “safe use” or “misuse”, a review 
committee made up of two geriatric pharmacotherapists and one OTC medication expert will 
be used to independently adjudicate the primary outcome. The review committee will be 
provided with the name of the OTC medication that participants select, a description of how 
the participant intends to use the OTC medication from the older adult interviews, and the 
self-reported disease, prescription, and OTC medication list provided on the medical/
demographic form. The review committee will be blinded to the participant’s status as a 
baseline or post-intervention participant to help guard against information bias.
The impact of the intervention will be assessed using a multi-level logit model with a two-
level structure. Comparisons between the baseline and post-intervention cohorts will be 
made, nested within pharmacist. Total and type of misuse will be quantified and compared, 
to determine if the intervention reduces the frequency or instances of concurrent misuse.
Older Adult Decision Making Process and Pharmacist Recommendation 
Characteristics: These outcomes will be analyzed the same way as in the beta phase.
Aim 3. Evaluate the implementation of a system redesign intervention in 
community pharmacies—The purpose of the test phase implementation assessment is to 
determine the degree of success or failure through an analysis of the summative data results 
collected at the end of the project. The summative data collected will be guided by the 
taxonomy of implementation outcomes proposed by Proctor et al, with both quantitative and 
qualitative data sources.21
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Sample Size Calculation—Unlike a hypothesis-testing quantitative study, there is no 
method for calculating power or sufficient sample sizes for qualitative data such as 
interviews or observations. Based on the experience of having conducted extensive 
pharmacy observation and interview studies, the allotted time of one hour each for 9 
pharmacist interviews, 6 technician interviews, 3 store manager interviews, and one 
administrator interview and the number of observations (four 3-hour observations per 
pharmacy for a total of 12 observations) is believed to be sufficient.
Data Collection and Analysis—The same implementation outcomes will be collected 
and analyzed, as in the beta test. These included outcomes of acceptability, adoption, 
appropriateness, feasibility, fidelity, and cost.
Dissemination and Implementation Plan
It is believed if this intervention works, as it should, the dissemination and implementation 
plan, will lead to widespread adoption, which is the long term goal. Scaling up the 
intervention throughout 80+ stores in Wisconsin will be the first step, and the plan is 
designed to facilitate such scaling within the company organization. Accordingly, the 
primary targets will be company pharmacists and older adults.
There are three key features needed to disseminate the results to pharmacists.
1. A champion at the organizational level: A champion at the organizational level 
has been shown in numerous health care innovation studies to be an essential 
element.51
2. Mentored coaching by experienced pharmacists: In addition to an organizational 
champion, widespread implementation will require credible coaches to promote 
the success and sustainability of the intervention. Coaches will be recruited from 
the study pharmacists who have experience with the intervention.52
3. An implementation toolkit: An intervention toolkit will be developed specifically 
for scalability for stores, and made available through websites affiliated with the 
Agency for Healthcare Research and Quality and other entities championing 
patient safety.
Further, the successful implementation of this intervention in the partnering store in 
Wisconsin may generate significant positive publicity regarding the importance of OTC 
medication safety in older adults, and the vital role of community pharmacists in decreasing 
misuse. Similar to the widespread publicity and response by the medical community 
surrounding CVS’s removal of tobacco products,16,53,54 this study could lead to a shift in the 
marketplace to add an OTC medication safety emphasis into health and wellness initiatives 
and policies.
In order to set the stage for further spread to other organizations, the research team will 
begin disseminating preliminary data and formative implementation insights in year 2 and 3 
of the study in scientific journal and at national meetings. Results will also be shared with 
older adults in the community through organizations that serve older adults.
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Limitations
A randomized controlled trial and cohort designs were not considered in this study due to 
the methodological limitation of being unable to randomize and to observe and track 
changes within a given participant. Limitations of using a pre/post study design include the 
potential for confounders, and the risk that participants in the baseline and post-intervention 
data collections are not equal.
In prior studies using the same recruitment plan,35 there was a rapid recruitment of 20 older 
adults in 4 weeks. Of older adults who were interested in participating, 100% completed 
data collection. Additional recruitment steps were added for this proposal including the 
addition of a store research liaison who will be a familiar face to potential participants and 
will field questions about the study prior to consent. Further, since this recruitment strategy 
is familiar to the research team, no delays when seeking human subject approval are 
anticipated. As a result, it is believed that recruitment for this study will be very feasible.
There is a recognition that OTC medications can be purchased at retail establishments that 
do not have pharmacies (e.g., convenience stores, gas stations). Therefore, the intervention is 
not generalizable to those settings. However, if successful, there is great potential for the 
intervention to be implemented in community pharmacies in national chain, independent, 
mass merchandise, and grocery stores that are ubiquitous in both urban and rural 
communities. Further, the recruitment strategy will result in asking older adults to opt-in to 
participating in the study. The research team recognizes that self-section of this group that 
may not be generalizable to the entire population.
Integration of the clinical decision tool in practice will take time, and enforcement of the 
clinical decision tool may be difficult to achieve. While the purpose of the tool is to decrease 
OTC medication misuse, it is believed that the introduction of the tool is an opportunity to 
improve efficiency, helping the pharmacist to quickly gather relevant information to make a 
safe recommendation. The pharmacy stakeholders in the participatory design process will 
inform how it is integrated.
There is potential that pharmacists and technicians will interact with study participants 
differently than nonparticipants, if they note that participants are with researchers. The data 
collected on the OTC encounter form will be used as a reliability check to assess this 
concern.
Self-report and recall bias are limitations with using the older adult medical/demographic 
form; however, the design will most likely result in underestimating potential misuse. 
Additionally, the surveys were selected in order to limit their burden.
Projected Impact
We anticipate that this project, which focuses on achieving systems-based improvement in 
an underemphasized area of the medication use process, will generate critical data that will 
shed light on a potentially enormous but invisible patient safety concern.
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Our preliminary work allows us to test an intervention that is guided by both theory and pilot 
data. We will leverage the knowledge, skills, and accessibility of pharmacists, who are a 
ubiquitous, yet underutilized community resource, and who are valued as one of the most 
trusted health care professionals.55
Completion of this study will provide evidence that OTC medication safety in older adults 
can be improved, and will provide a road map for pharmacy organizations to do so. 
Ultimately, we believe that the successful completion of this study will reduce ADEs 
associated with inappropriate OTC medication use in older adults.
Adverse drug events (ADEs) associated with over-the-counter (OTC) medications cause 
178,000 hospitalizations each year. In this study, a system redesign intervention to decrease 
high-risk OTC medication misuse is proposed. This paper describes a protocol for a hybrid 
design study evaluating both the effectiveness and implementation of a system redesign 
intervention in community pharmacies. A pre (control)/post (intervention) test will 
determine the effectiveness of the intervention. The primary outcome will be OTC 
medication misuse. The process of implementation in the community pharmacy setting will 
be described using the implementation taxonomy proposed by Proctor et al.
Acknowledgments
The authors would like to thank members of the research team who provided valuable comment on the research 
protocol: Steven Albert, Roger Brown, Pascale Carayon, Nora Jacobson, Corey Lester, Jane Mahoney, Cynthia 
Phelan, and Ken Walker.
Funding
This work was supported by the Agency for Healthcare Research and Quality (AHRQ), grant 1R18HS024490-01, 
and by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for 
Advancing Translational Sciences (NCATS), grant UL1TR000427. RJH is supported by grant K01AG044439 from 
the National Institute on Aging (NIA) of the US National Institutes of Health (NIH). The content is solely the 
responsibility of the authors and does not necessarily represent the official views of the NIH.
Bibliography & References Cited
1. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and 
over-the-counter medications and dietary supplements among older adults in the United States. 
JAMA. 2008; 300:2867–2878. [PubMed: 19109115] 
2. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication 
use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002; 
287:337–344. [PubMed: 11790213] 
3. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among 
older persons in the ambulatory setting. JAMA. 2003; 289:1107–1116. [PubMed: 12622580] 
4. U.S. Department of Health and Human Services: Office of Disease Prevention and Health 
Promotion. National action plan for adverse drug event prevention. Washington, DC: 2014. 
5. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a 
United States multicenter, prospective study. Hepatology. 2005; 42:1364–1372. [PubMed: 
16317692] 
6. Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (Paracetomal)-associated 
overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006; 15:398–405. [PubMed: 
16294364] 
Chui et al. Page 14
Res Social Adm Pharm. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
7. Serper M, McCarthy DM, Patzer RE, et al. What patients think doctors know: beliefs about provider 
knowledge as barriers to safe medication use. Patient Educ Couns. 2013; 93:306–311. [PubMed: 
23890725] 
8. Kantar Health. National health and wellness survey: US, 2012. Princeton, NJ: 2013. 
9. Sleath B, Rubin RH, Campbell W, Gwyther L, Clark T. Physician-patient communication about 
over-the-counter medications. Soc Sci Med. 2001; 53:357–369. [PubMed: 11439819] 
10. Andersen RM, Yu H, Wyn R, Davidson PL, Brown ER, Teleki S. Access to medical care for low-
income persons: how do communities make a difference? Med Care Res Rev. 2002; 59:384–411. 
[PubMed: 12508702] 
11. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 
2003; 348:1556–1564. [PubMed: 12700376] 
12. Guirguis K. The use of nonprescription medicines among elderly patients with chronic illness and 
their need for pharmacist interventions. Consult Pharm. 2010; 25:433–439. [PubMed: 20601348] 
13. NCPIE. Uses and attitudes about taking over-the-counter medicines: Findings of a 2003 national 
opinion survey. 2003. http://www.bemedwise.org/survey/summary_survey_findings.pdf
14. Alexander, A. Hamacher Resource Group enhances category management program to assist 
independents. 2014. http://www.drugstorenews.com/article/hamacher-resource-group-enhances-
category-management-program-assist-independents. Accessed 2014
15. Johnson MM, Drungle SC. Purchasing over-the-counter medications: the influence of age and 
familiarity. Exp Aging Res. 2000; 26:245–261. [PubMed: 10919069] 
16. Brennan TA, Schroeder SA. Ending sales of tobacco products in pharmacies. JAMA. 2014; 
311:1105–1106. [PubMed: 24500655] 
17. Twigg MJ, Bhattacharya D, Desborough JA, Wright D. A drop-in clinic for patients with poorly-
controlled diabetes: a community pharmacy feasibility study. Int J Clin Pharm. 2015; 37:395–402. 
[PubMed: 25666943] 
18. The Gerontological Society of America. GSA and CHPA National summit: OTC medication 
behaviors of older adults. Washington DC: 2013. Over-the-counter medication behaviors of older 
adults: research is needed to better understand and promote safe and effective use. 
19. Knudsen P, Herborg H, Mortensen AR, Knudsen M, Hellebek A. Preventing medication errors in 
community pharmacy: root-cause analysis of transcription errors. Qual Saf Health Care. 2007; 
16:285–290. [PubMed: 17693677] 
20. Nester TM, Hale LS. Effectiveness of a pharmacist-acquired medication history in promoting 
patient safety. Am J Health Syst Pharm. 2002; 59:2221–2225. [PubMed: 12455306] 
21. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual 
distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011; 
38:65–76. [PubMed: 20957426] 
22. Holden RJ, Carayon P, Gurses AP, et al. SEIPS 2.0: a human factors framework for studying and 
improving the work of healthcare professionals and patients. Ergonomics. 2013; 56:1669–1686. 
[PubMed: 24088063] 
23. Odukoya OK, Stone JA, Chui MA. Barriers and facilitators to recovering from e-prescribing errors 
in community pharmacies. J Am Pharm Assoc (2003). 2015; 55:52–58. [PubMed: 25539495] 
24. Chui MA, Mott DA, Maxwell L. A qualitative assessment of a community pharmacy cognitive 
pharmaceutical services program, using a work system approach. Res Social Adm Pharm. 2012; 
8:206–216. [PubMed: 21824822] 
25. Holden RJ, Schubert CC, Mickelson RS. The patient work system: an analysis of self-care 
performance barriers among elderly heart failure patients and their informal caregivers. Appl 
Ergon. 2015; 47:133–150. [PubMed: 25479983] 
26. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid 
designs: combining elements of clinical effectiveness and implementation research to enhance 
public health impact. Med Care. 2012; 50:217–226. [PubMed: 22310560] 
27. Glasgow RE, Lichtenstein E, Marcus AC. Why don’t we see more translation of health promotion 
research to practice? Rethinking the efficacy-to-effectiveness transition. Am J Public Health. 2003; 
93:1261–1267. [PubMed: 12893608] 
Chui et al. Page 15
Res Social Adm Pharm. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28. Stetler CB, Legro MW, Wallace CM, et al. The role of formative evaluation in implementation 
research and the QUERI experience. J Gen Intern Med. 2006; 21(Suppl 2):S1–8.
29. Wickens, CD., Gordon, SE., Liu, Y. An introduction to human factors engineering. Upper Saddle 
River, N.J.: Pearson Prentice Hall; 2004. 
30. Chui MA, Stone JA, Martin BA, Croes KD, Thorpe JM. Safeguarding older adults from 
inappropriate over-the-counter medications: the role of community pharmacists. Gerontologist. 
2014; 54:989–1000. [PubMed: 24197014] 
31. Hales BM, Pronovost PJ. The checklist–a tool for error management and performance 
improvement. J Crit Care. 2006; 21:231–235. [PubMed: 16990087] 
32. Karsh BT. Beyond usability: designing effective technology implementation systems to promote 
patient safety. Qual Saf Health Care. 2004; 13:388–394. [PubMed: 15465944] 
33. Community Advisors on Research Design and Strategy. http://winrs.son.wisc.edu/services/cards/. 
Accessed 2016
34. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS 
multidimensional functional assessment questionnaire. J Gerontol. 1981; 36:428–434. [PubMed: 
7252074] 
35. Stone JA, Lester CA, Aboneh EA, Phelan CH, Welch LL, Chui MA. A preliminary examination of 
over the counter medication misuse rates in older adults. Res Social Adm Pharm. 2016
36. Kassam R, Collins JB, Berkowitz J. Patient satisfaction with pharmaceutical care delivery in 
community pharmacies. Patient Prefer Adherence. 2012; 6:337–348. [PubMed: 22563242] 
37. Odukoya OK, Stone JA, Chui MA. How do community pharmacies recover from e-prescription 
errors? Res Social Adm Pharm. 2014; 10:837–852. [PubMed: 24373898] 
38. Wetterneck TB, Lapin JA, Krueger DJ, Holman GT, Beasley JW, Karsh BT. Development of a 
primary care physician task list to evaluate clinic visit workflow. BMJ Qual Saf. 2012; 21:47–53.
39. Holden RJ, Brown RL, Scanlon MC, Karsh BT. Pharmacy workers’ perceptions and acceptance of 
bar-coded medication technology in a pediatric hospital. Res Social Adm Pharm. 2012; 8:509–
522. [PubMed: 22417887] 
40. Chui, MA., Stone, JA., Thorpe, JM., Martin, BA. Exploring work system barriers to effective over-
the-counter counseling. Human Factors and Ergonomics Annual Meeting; 2013; San Diego. 
41. Maxwell L, Odukoya OK, Stone JA, Chui MA. Using a conflict conceptual framework to describe 
challenges to coordinated patient care from the physicians’ and pharmacists’ perspective. Res 
Social Adm Pharm. 2014; 10:824–836. [PubMed: 24440119] 
42. Chui MA, Stone JA. Exploring information chaos in community pharmacy handoffs. Res Social 
Adm Pharm. 2014; 10:195–203. [PubMed: 23665076] 
43. Lexi-Comp I. (Lexi-Drugs(R)). Lexi-Comp, Inc; 
44. American Geriatrics Society. American Geriatrics Society updated Beers Criteria for potentially 
inappropriate medication use in older adults. J Am Geriatr Soc. 2012; 60:616–631. [PubMed: 
22376048] 
45. Crandall, B.Klein, GA., Hoffman, RR., editors. Working minds a practitioner’s guide to cognitive 
task analysis. Cambridge, Mass: MIT Press; 2006. 
46. Hoffman, RR., Militello, LG. Perspectives on cognitive task analysis: historical origins and modern 
communities of practice. New York: Psychology Press; 2009. 
47. Shepherd, A. Hierarchical task analysis. London; New York: Taylor & Francis; 2001. 
48. Odukoya OK, Stone JA, Chui MA. E-prescribing errors in community pharmacies: exploring 
consequences and contributing factors. Int J Med Inform. 2014; 83:427–437. [PubMed: 24657055] 
49. Chui MA, Stone JA. The prescription handoff in community pharmacy: a study of its form and 
function. J Am Pharm Assoc (2003). 2012; 52:e161–167. [PubMed: 23229978] 
50. Patton, MQ. Qualitative research and evaluation methods. Thousand Oaks, Calif: Sage 
Publications; 2002. 
51. Holland R, Meyers D, Hildebrand C, Bridges AJ, Roach MA, Vogelman B. Creating champions for 
health care quality and safety. Am J Med Qual. 2010; 2:102–108.
Chui et al. Page 16
Res Social Adm Pharm. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
52. Li J, Hinami K, Hansen LO, Maynard G, Budnitz T, Williams MV. The physician mentored 
implementation model: a promising quality improvement framework for health care change. Acad 
Med. 2015; 90:303–310. [PubMed: 25354069] 
53. Young, CA. Walgreens expands flagships, other Well Experience stores. 2013. http://
www.pharmacist.com/walgreens-expands-flagships-other-well-experience-stores. Accessed 2015
54. Johnsen, M. Rite Aid continues evolving Wellness store format 2014. http://
www.retailingtoday.com/article/rite-aid-continues-evolving-wellness-store-format. Accessed 2015
55. Smith M, Bates DW, Bodenheimer T, Cleary PD. Why pharmacists belong in the medical home. 
Health Aff (Millwood). 2010; 29:906–913. [PubMed: 20439879] 
Chui et al. Page 17
Res Social Adm Pharm. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Research Design Overview
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Table 1
Effectiveness and Implementation Outcomes
Effectiveness Outcome Definition Data Source
OTC Medication Misuse One or more of the following:
• Drug-drug interaction
• Drug-disease interaction
• Drug-age interaction
• Reported use exceeds 
product labeling guidelines
• Older Adult Interview
• Older Adult Medical/Demographics form 
(disease list, medication list)
Older Adult Decision Making 
Process
Knowledge and strategies required to 
select a safe OTC medication
• Older Adult Interview
Recommendation characteristics Type and confidence of recommendation • Older Adult Interview
• Pharmacist OTC Encounter Form
Implementation Outcome Definition Data Source
Acceptability Satisfaction with aspects of innovation • Pharmacist/Technician Tool Acceptance 
Survey
• Pharmacist Interviews
• Older Adult Satisfaction Survey
Adoption Intention to try the innovation • Pharmacist/Technician Observation
• Pharmacist/Technician Tool Acceptance 
Survey
• Pharmacist/Technician/Manager Interviews
Appropriateness Perceived fit, compatibility, practicability • Pharmacist/Technician Observation
• Pharmacist/Technician Tool Acceptance 
Survey
• Pharmacist/Technician/Manager Interviews
Feasibility Actual fit; the extent to which an 
innovation can be successfully used
• Pharmacist/Technician Tool Acceptance 
Survey
• Pharmacist/Technician/Manager Interviews
• Pharmacist OTC Encounter Form
Fidelity Innovation delivered as intended; quality 
of innovation delivery
• Pharmacist/Technician Observation
• Pharmacist/Technician/Manager Interviews
• Pharmacist OTC Encounter Form
Cost Innovation delivery costs, overhead costs • Shopko Organization Data
• Pharmacist OTC Encounter Form
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